
CLAIMS


1. Use of ~~A~~ a RXR agonist of Formula I,



(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof in the preparation of a medicament, for ~~use in~~ treating a patient with $Her2^+$ cancer, wherein the patient has received, is receiving, or is scheduled to receive a Her2-targeted therapeutic agent.


2. Use of ~~A~~ a RXR agonist of Formula I,



(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, in the preparation of a medicament for ~~and a Her2-targeted therapeutic agent for use in combination in~~ treating a patient with $Her2^+$ cancer, wherein said RXR agonist is to be used in combination with a Her2-targeted therapeutic agent.

~~3. A Her2-targeted therapeutic agent for treating $Her2^+$ cancer in a patient with $Her2^+$ cancer, with a therapeutic response less than a complete response to treatment with a RXR agonist of Formula I,~~




~~(Formula I)~~

~~wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof,~~

~~in combination with the RXR agonist.~~

~~4. A RXR agonist of Formula I,~~



~~(Formula I)~~

~~wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof, for treating Her2+ cancer in a patient with Her2+ cancer, with a therapeutic response less than a complete response to treatment with a Her2-targeted therapeutic agent,~~

~~in combination with the Her2-targeted therapeutic agent.~~


~~5.~~3. The ~~RXR agonist~~use of any one of claims 1~~-4~~ or 2, wherein thyroid hormone is to be administered in conjunction with the RXR agonist.

~~6.~~4. The ~~RXR agonist~~use of claim ~~5~~3, wherein the thyroid hormone is thyroxine.

~~7. The RXR agonist of any one of claims 1-6, wherein the RXR agonist is a compound of Formula I.~~

~~8. The RXR agonist of any one of claims 1-6, wherein the RXR agonist is pharmaceutically-acceptable salt of a compound of Formula I.~~

~~9.~~5. The ~~RXR agonist~~use of any one of claims 1~~-6~~4, wherein the RXR agonist is a compound of Formula II



(Formula II).

~~10.~~6. The ~~Her2-targeted therapeutic agent~~use of any one of claims 1~~-9~~ 5 ~~comprising~~ wherein an anti-Her2 therapeutic antibody is to be further administered.

~~11.~~7. The use ~~Her2-targeted therapeutic agent~~ of claim ~~10~~6, wherein the therapeutic antibody is trastuzumab or pertuzumab.

~~12.~~8. The use ~~Her2-targeted therapeutic agent~~ of any one of claims 1~~-9~~5, wherein ~~comprising~~ an antibody-drug conjugate is to be further administered, wherein the

antibody is an anti-Her2 antibody.

~~13.~~9. The use ~~Her2-targeted therapeutic agent~~ of claim ~~12~~8, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.


~~14.~~10. The use ~~Her2-targeted therapeutic agent~~ of any one of claims 1-9, wherein a ~~comprising a~~ Her2 kinase inhibitor is to be further administered.

~~15.~~11. The use ~~Her2-targeted therapeutic agent~~ of claim ~~14~~10, wherein the Her2 kinase inhibitor is lapatinib or neratinib.

~~16. The RXR agonist and/or Her2-targeted therapeutic agent of any one of claims 1-15, wherein the Her2$^+$ cancer is Her2$^+$ breast cancer.~~

~~17. The RXR agonist and/or Her2-targeted therapeutic agent of any one of claims 1-15, wherein the Her2$^+$ cancer is Her2$^+$ gastroesophageal cancer, ovarian cancer, stomach cancer, adenocarcinoma of the lung, uterine cancer, serous endometrial carcinoma, or salivary duct carcinoma.~~

~~18.~~12. A combination comprising a Her2-targeted therapeutic agent and a RXR agonist of Formula I,




(Formula I)

wherein R is H, or lower alkyl of 1 to 6 carbons; or a pharmaceutically-acceptable salt thereof.

~~19.~~13. The combination of claim ~~18~~12, further comprising thyroid hormone.

~~20.~~14. The combination of claim ~~18~~12, wherein the RXR agonist is a compound of Formula II



(Formula II).

~~21.~~15. The combination of claim ~~18~~12, wherein the Her2-targeted therapeutic agent comprises an anti-Her2 therapeutic antibody selected from trastuzumab or pertuzumab.

~~22. The combination of claim 21, wherein the therapeutic antibody is trastuzumab or pertuzumab.~~

~~23.~~16. The combination of claim ~~18~~12, wherein the Her2-targeted therapeutic agent comprises an antibody-drug conjugate wherein the antibody is an anti-Her2 antibody comprising ado-trastuzumab emtansine.

~~24. The combination of claim 23, wherein the antibody-drug conjugate is ado-trastuzumab emtansine.~~

~~25.~~17. The combination of claim ~~18~~12, wherein the Her2-targeted therapeutic agent comprises a Her2 kinase inhibitor selected from lapatinib or neratinib.

~~26. The combination of claim 25, wherein the Her2 kinase inhibitor is lapatinib or neratinib.~~